Jump to content
  • Sign Up
  • Posts

    • has anyone noticed something experiencing this unusual condition with them? First time I have seen something like this and the thing is erythema is extended to arms and the redness is not causing any pain and itchiness and the startling thing is I get intense erythema on my right cheek than my left cheek and  the erythema on my right hand is more than the left hand. So I was observing, has right face erythema anything to do with right hand erythema? Does it have any connection in common?
    • [Acne rosacea-a pedigree with ten cases]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2019 Jul 10;36(7):747 Authors: Xia R, Cao L, Fang L, Xiong H, Yang L PMID: 31302927 [PubMed - in process] {url} = URL to article
    • Treatment of Rhinophyma With Surgical Excision and Amniotic Membrane. J Craniofac Surg. 2019 Jul;30(5):1563-1564 Authors: Yoo JJ, Thaller SR Abstract Rhinophyma is a phenotypic subtype of rosacea affecting the nose. It is characterized by phymatous changes, skin thickening/fibrosis, glandular hyperplasia, and chronic inflammation. Treatment of severe rhinophyma is predominantly surgical excision with closure by secondary intention. Amniotic membrane has been used to promote wound healing, fibrosis, and inflammation. In this case study, the authors present a 63-year-old male with longstanding rhinophyma treated with surgical excision with intraoperative placement of amniotic membrane. PMID: 31299768 [PubMed - in process] {url} = URL to article
    • Difference in Vasoconstrictors: Oxymetazoline vs Brimonidine. J Dermatolog Treat. 2019 Jul 11;:1-23 Authors: Okwundu N, Cline A, Feldman SR Abstract OBJECTIVE: Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine. METHOD AND MATERIALS: Phase II and phase III clinical studies evaluating oxymetazoline and brimonidine were assessed to compare their efficacy and safety. RESULTS: In their respective phase III trials, both oxymetazoline and brimonidine met the primary efficacy outcome of having at least a 2-grade decrease from baseline on both the Clinician Erythema Assessment and the Subject Self-Assessment Scales compared to the vehicle control. Treatment related adverse events of oxymetazoline and brimonidine are most often mild and localized. CONCLUSION: Topical oxymetazoline and brimonidine are effective for the management of persistent facial erythema associated with rosacea with a few mild and localized adverse effects. Further long term research is imperative to further understand their long term effects. PMID: 31294643 [PubMed - as supplied by publisher] {url} = URL to article
    • Acne and rosacea: What's new for treatment? Dermatol Ther. 2019 Jul 11;:e13020 Authors: Dursun R, Daye M, Durmaz K Abstract Acne and rosacea are two well-known chronic skin diseases in dermatology. There are many known therapeutic options of both diseases, but new treatment agents and therapeutic advances come to the agenda day by day. We would like to summarize new treatment advances for acne and rosacea diseases. This article is protected by copyright. All rights reserved. PMID: 31294907 [PubMed - as supplied by publisher] {url} = URL to article
×
×
  • Create New...